Nitric oxide (NO) plays a pivotal role in main- taining balance of physiological events in many systems including the autonomic, cardiovas- cular, hematological, and pulmonary systems. Lipopolysaccharide (LPS) and peptidoglycan (PGN), components of the outer cell membranes of Gram-negative bacteria and cell walls of Gram-positive bacteria respectively, are in- criminated in NO-induced septic shock. Ne- bivolol is a third generation β1- adrenoceptor blocker with a vasodilatory property attributed to enhanced availability of nitric oxide and re- duction of cellular oxidative stress through an unknown mechanism. The current study ex- plored the hypothesis that if nebivolol enhances the availability of NO, pretreatment with ne- bivolol may enhance production of NO in re- sponse to subsequent treatment with LPS and PGN, an observation that may have relevance in clinical septic shock. Groups of female BALB/c mice each containing 12 mice (6-8 weeks old) were injected intraperitoneally with LPS (30 µg/mouse), PGN (100 µg/mouse), nebivolol (0.25 µg/g, 0.35 µg/g, 0.7 µg/g), LPS and nebivolol (0.25 µg/g), LPS and nebivolol (0.35 µg/g), LPS and nebivolol (0.7 µg/g), PGN and nebivolol (0.25 µg/g), PGN and nebivolol (0.35µg/g). One group of mice was injected with saline and an- other served as control. Three mice from each group were bled 1, 3, 6 and 9 hours post-injec- tion, the blood was pooled and the nitrite serum levels, reflecting NO concentration, were de- termined using Greiss reagent. The following results were obtained: 1) Treatment with saline did not induce NO production; 2) LPS induced NO production to a maximal limit of 545% at 9 hours as compared to treatment with saline; 3) PGN did not induce NO production; 4) nebivolol at most doses and periods (7 out of 10 deter- minations) increased NO production over a range of 18-110% as compared to treatment with saline; 5) Nebivolol enhanced LPS-induced production of NO by 58% at a dose of 0.7 µg/gm at 9 hours. It is concluded that nebivolol in- duces NO production. At low doses nebivolol initially appeared to have a suppressive or no effect on NO production induced by LPS. In- crease in the dose of nebivolol resulted in augmentation of LPS-induced production of NO. PGN, in the dose tested, did not have an effect on NO production.
Furchgott, R.F., Zawadzki, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
Ignarro, L. (1990) Nitric Oxide: A novel transduction mechanism for transcellular communication. Hyper- tension, 16, 477-483.
Hobbs, A., Higgs, A. and Moncada, S. (1999) Inhibition of nitric oxide synthase as a potential therapeutic target. Annual Review Pharmacology Toxicology, 39, 191-220.
Maffei, A. and Lembo, G. (2009) Nitric oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease, 10, 1-11.
Falciani, M., Rinaldi, B. D., Agostino, B., Mazzeo, F., Rossi, S. and Nobili, B. (2001) Effects of nebivolol on human platelet aggregation. Journal of Cardiovascular Pharmacology, 38, 922-929.
Ignarro, J., Sisodia, M., Trinh, K., Bedrood, S., Wu, G., Wei, L. and Buga, G. (2002) Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide, 7, 83-90.
Mercanoglu, G., Safran, N., Gungor, M., Pamukcu, B., Uzun, H. and Sezgin, C. (2008) The effects of nebivolol on apoptosis in a rat infarct model. Circ J., 72, 660-670.
Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P. and Cook, S. (2007) Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovascular Drugs and Therapy, 21, 99-108.
Hancock, C.M. and Walsh, D.A. (2008) Modulation of pain in osteoarthritis: the role of nitric oxide. Clinical Journal of Pain, 24, 353-365.
Szabo, C. and Radi, R. (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nature Reviews Drug Discovery, 6, 662-680.
Mackenzie, I., Rutherford, D. and MacDonald, T. (2008) Nitric Oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Research & Therapy, 10, 2.
Guix, F., Uribesalgo, I., Coma, M. and Munoz, F. (2005) The physiology and pathophysiology of nitric oxide in the brain. Progress in Neurobiology, 76, 126-152.
Raetz, C.R.. (1990) Biochemistry of endotoxin. The Annual Review of Biochemistry, 59, 129-170.
Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nature Reviews Immunology, 4, 499-511.
Jiang, Z., Georgel, P., Du, X., Shamel, L., Sovath, S., Mudd, S., Huber, M., Kalis, C., Keck, S., Galanos, C., Freudenberg, M. and Beutler, B. (2005) CD14 is required for MyD88-inde- pendent LPS signaling. Nature Immunolog, 6, 565-570.
Kitchens, R.L., Thompson, P.A., O’Keefe, G.E. and Munford, R.S. (2000) Plasma constituents regulate LPS binding to, and release from, the monocyte cell surface. Journal of Endotoxin Research, 6, 477-482.
Mangrella, M., Rossi, F., Fici, F. and Rpssi, F. (1998) Pharmacology of nebivolol. Pharmacological Research, 38, 6.
Broeders, M., Doevendans, P.A. and Van Der Zee, R. (2000) Nebivolol: A third generation beta-blocker that augments vascular no release. Circulation, 102, 677-684.
Maffei, A., Pardo, A., Carangi, R., Lembo, G., Carullo, P., Poulet, R., Gentile, M. and Vecchione, G. (2007) Nebivolol induces Nitric Oxide release in the heart through inducible Nitric Oxide synthase activation. Hypertension, 50, 652- 656.
Weiss, R. (2006) Nebivolol: A novel beta-blocker with nitric Oxide-induced vasodilatation. Vascular Health and Risk Management, 2, 303-308.
Veverka, A. and Salinas, J. (2007) Nebivolol in treatment of chronic heart failure. Vascular Health and Risk Man- agement, 3, 647-654.
Agabiti-Rosei, E., Porteri, E. and Rizzoni, D. (2009) Arterial stiffness, hypertension, and rational use of nebivolol. Vascular Health and Risk Management, 5, 353-360.
Zanchetti, A. (2004) Clinical pharmacodynamics of ne- bivolol. Blood Pressure Supplies, 1, 17-32.
Gupta, S. and Wright, H.M. (2008) Nebivolol: A highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing Nitric Oxide. Cardiovascular Therapeutics, 26, 189-202.
Papademetriou, V. (2008) Beta blockers in management of hypertension: Focus on nebivolol. Expert Review of Cardiovascular Therapy, 6, 471-479.
Judy, W.M. Cheng, B.S. (2009) Nebivolol: A third-gen- eration P-Blocker for hypertension. Clinical Therapeu- tics, 31, 3.
Ladage, D., Brixius, K., Hoyer, H., Steingen, C., Wesseling, A. and Malan, D. (2006) Mechanisms underlying nebivolol-induced endothelial Nitric Oxide synthase activation in human umbilical vein endothelial cells. Clinical and Experimental Pharmacology and Physiology, 33, 720-724
Ignarro, J., Sisodia, M., Trinh, K., Bedrood, S., Wu, G., Wei, L. and Buga, G. (2002) Nebivolol inhibits vascular smooth muscle cell proliferation by Mechanisms involving Nitric Oxide but not cyclic GMP. Nitric Oxide, 7, 83-90.
Maffei, A. and Lembo, G. (2009) Nitric Oxide mechanisms of nebivolol. Therapeutic Advances in Cardiovascular Disease, 10, 1-11.
Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P. and Cook, S. (2007) Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovascular Drugs and Therapy, 21, 99-108.
Maffei, A., Vecchione, C., Aretini, A., Poulet, R., Bettarini, U. and Gentile, M.T. (2006) Characterization of nitric oxide release by nebivolol and its metabolism. American Journal of Hypertension, 19, 579-586.
Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C. and Ogawa, H. (2002) Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. The Journal of Clinical Investigation, 109, 1351-1359.
Tzemos, N., Lim, P.O. and MacDonald, T.M. (2001) Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double-blind, crossover study. Circulation, 104, 511-14.
MacMicking, J.D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D.S., Trumbauer, M., Stevens, K., Xie, Q.W., Sokol, K. and Hutchinson, N. (1997) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell, 8, 641-650.
Cobb, J.P. and Danner, R.L. (1996) Nitric oxide and septic shock. The Journal of the American Medical Association, 275, 1192-1196.
Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nature Reviews Immunology, 4, 499-511.
Bagchi, A., Herrup, E., Warren, E., Trigilio, J., Shin, H., Valentine, C. and Hellman, J. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. The Journal of Immunology, 178, 1164-1171.
Kawai, T., Adachi, O., Ogawa, T., Takeda, K. and Akira. S. (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115-122.
Kreutz, M., Ackermann, U., Hauschildt, S., Krause, S.W., Riedel, D., Bessler, W. and Andreesen, R. (1997) A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology, 92, 396-401.
Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Huffel, C.V., Du, X., Birdwell, D., Alejos, E., Silva, M. and Galanos, C. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 282, 2085-2088.
Guix, F., Uribesalgo, I., Coma, M. and Munoz, F. (2005) The physiology and pathophysiology of nitric oxide in the brain. Progress in Neurobiology ,76, 126-152
Manni, M. and Maestroni, G. (2008) Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: Involvement of β-adrenoceptors and relevance in inflamematory diseases. Brain, Behavior, and Immunity, 22, 80-88.
Fahmi, H., Ancuta, P. and Chaby, R. (1996) Preexposure of mouse peritoneal macrophages to lipopolysaccharide and other stimuli enhances nitric oxide response to secondary stimuli. Inflammation Research, 45, 347-356.
Ida, A.J., Giebelen, Masja, L., Mark, C.D., Joost, C.M., Meijers, M.L., Christian, D., Sonja, von A. and Tom van der P. (2008) Endogenous adrenergic receptors inhibit LPS-induced pulmonary cytokine release and coagulation. AJRCMB Articles in Press.
Arai, K., Wood, J.P. and Osborne, N.N. (2003) Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Research, 985, 176-86.
Palsson-McDermott, E. and O’Neill, L. (2004) Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology, 113, 153-162.
Dziarski, R. and Gupta, D. (2005) Peptidoglycan recognition in innate immunity. Journal of Endotoxin Research, 11, 304-310.
Dziarski, R. and Gupta, D. (2005) Staphylococcus aureus peptidoglycan is a toll-like receptor 2 activator: A reevaluation. Infection and Immunity, 73, 5212-5216.